RxDoctor Payments Data
★ My doctorsLook up a doctor →

Evangeline Reyes, MD

Internal Medicine · Corona, CANPI 1144224908

Payments from drug & device makers

$67,304in general payments, 2019–2025

Across 927 payments — averaging $72.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Puma Biotechnology, Inc.$40K
  • Takeda Pharmaceuticals U.S.A., Inc.$7K
  • Bristol Myers Squibb$4K
  • Novartis$2K
  • Merck$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$16,90397%
  • Education$5153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Puma Biotechnology, Inc.10$40,037
Takeda Pharmaceuticals U.S.A., Inc.14$7,323
Bristol Myers Squibb40$3,709
Novartis106$1,842
Merck64$1,318
E.r. Squibb & Sons, L.L.C.89$1,289
Sanofi58$984
Johnson & Johnson(2 entities)33$804
GSK46$787
AstraZeneca(2 entities)38$713
Pfizer44$600
Amgen27$576
Seagen Inc.23$540
Pharmacyclics LLC, An Abbvie Company24$522
Incyte Corporation23$481
Gilead(2 entities)22$376
Astellas Pharma US Inc14$359
Genentech USA, Inc.19$337
Rigel Pharmaceuticals, Inc.11$303
Boehringer Ingelheim15$288
AVEO Pharmaceuticals, Inc.12$274
Lilly USA, LLC17$271
AbbVie11$201
Beigene USA, Inc.9$184
Karyopharm Therapeutics Inc.7$158
Tersera Therapeutics LLC7$157
Regeneron Healthcare Solutions, Inc.7$144
Eisai Inc.8$142
Array Biopharma Inc7$139
Bayer7$136
Blueprint Medicines Corporation5$123
Dova Pharmaceuticals6$115
Exelixis Inc.7$115
EMD Serono, Inc.7$112
EUSA Pharma (US) LLC7$111
CSL Behring6$110
Octapharma USA, Inc.6$108
Dendreon Pharmaceuticals LLC5$102
Epizyme, Inc.5$102
Sanofi-aventis U.S. LLC1$100
Acrotech Biopharma Inc.4$82
Foundation Medicine, Inc.4$80
Daiichi Sankyo Inc.3$79
Sobi, Inc3$76
Immunocore Limited1$76
Ipsen Biopharmaceuticals, Inc3$63
Springworks Therapeutics, Inc.2$56
Taiho Oncology, Inc.3$56
Myovant Sciences Inc.3$51
Mirati Therapeutics, Inc.3$44
Pharmacosmos Therapeutics Inc.2$43
Myriad Genetic Laboratories, Inc.2$39
Mylan Institutional Inc.2$38
Sun Pharmaceutical Industries Inc.2$34
Pharmaessentia USA Corporation1$31
Global Blood Therapeutics, Inc.2$31
Aurobindo Pharma USA, Inc.2$30
Catalyst Pharmaceuticals, Inc.1$29
Jazz Pharmaceuticals Inc.1$28
Secura Bio, Inc.3$28

How this compares

$67,304 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Medicare billing

Part B allowed, 2024
$90,982
Medicare patients
48
Services billed
6,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole42$748
Pantoprazole Sodium11$72

Paid to pharmacies, not to this prescriber.

Other internal medicine in Corona

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →